GlassScriptPhysician profile
Tracy L Neal
NPI 1881664258
$6,323.46
in general payments reported to CMS, 2019-2025
37 companies · $912 in 2025
The $912 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $296 · 2021: $1,761 · 2022: $1,192 · 2023: $680 · 2024: $831 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,422.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,310.16 | 2021-2025 | Tyrx, Linq II, Cobalt Dr Mri Surescan |
| Merck Sharp & Dohme LLC | $773.60 | 2021-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $768.06 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $424.06 | 2022-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $419.49 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $307.70 | 2019-2025 | Accent, Assurity |
| Pfizer INC. | $298.73 | 2019-2025 | |
| Medtronic Vascular, INC. | $246.22 | 2019-2020 | |
| Amgen INC. | $239.97 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $154.19 | 2019-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $149.65 | 2023-2024 | |
| Cvrx, INC. | $135.97 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.21 | 2022-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $97.86 | 2025 | |
| Novo Nordisk INC | $94.77 | 2024-2025 | Wegovy |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $83.03 | 2021-2025 | Definity |
| Alnylam Pharmaceuticals INC. | $78.22 | 2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $71.31 | 2019-2024 | Xarelto |
| Philips North America LLC | $61.28 | 2019-2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Boston Scientific Corporation | $59.68 | 2024 | Watchman Flx |
| Corvista Health, INC. | $58.68 | 2025 | Corvista System |
| Elutia, INC. | $53.02 | 2019 | |
| Medicomp INC | $45.24 | 2019-2025 | Telepatch Cardiac Monitor |
| Regeneron Healthcare Solutions, INC. | $43.33 | 2019 | |
| Irhythm Technologies, INC. | $32.37 | 2019 | |
| Medline Industries LP | $24.11 | 2023 | |
| Convatec INC. | $23.78 | 2023 | |
| Vital Connect, INC | $19.87 | 2022 | |
| Bridgebio Pharma, INC. | $19.59 | 2025 | Attruby |
| Ge Healthcare | $18.65 | 2023 | |
| Cleerly, INC. | $17.83 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Terumo Medical Corporation | $17.78 | 2019 | |
| Osprey Medical INC | $17.10 | 2021 | |
| Baxter Healthcare | $15.66 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| G Medical Diagnostic Services, INC. | $14.71 | 2021 | |
| Scpharmaceuticals INC. | $13.42 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $13.16 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,733,397.16 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Neal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.